CCSN needs your help to improve our newsletter – please take our 5 minute survey and be entered into a draw for 1 of 5 $20 Amazon gift cards. Draw takes place Nov. 30. Help us reach the 400 entries we need. bit.ly/2QbCWQH
Information about breast density is an important part of breast cancer screening and ensuring early detection and treatment. That is why it will now be automatically included in a woman’s screening mammography report. Nova Scotia is the first province in Canada to use a software that assesses breast density and automatically shares results. “Breast health is a serious issue and it’s important to make sure
Date: October 7, 2019 Our file number: 19-119291-196 The purpose of this Notice of Amendment is to notify about the additions of acalabrutinib, galcanezumab, larotrectinib, mannitol, neratinib, niraparib, ravulizumab, romosozumab, and sodium zirconium cyclosilicate to the Prescription Drug List (PDL) for human and veterinary use. These additions are effective at the time of posting. Rationale: A scientific review of these drugs against the criteria set out in
Clinical Trials Ontario (CTO) has been working with health charities and patient organizations like CCSN to build tools and resources about clinical trials that are informed by and meet the needs of their communities. CCSN is one of the organizations that has been engaged from the start of these efforts, and this update is intended to help you see what this collaborative work has produced.
Ahead of the federal election, CCSN believes in the critical importance of raising key issues related to the mission of creating and maintaining the best standard of care for cancer patients, survivors and caregivers. As part of these efforts, CSSN has asked the parties and candidates for their stance on the following issues: Employment Insurance Sickness Benefits National Pharmacare Program Youth Vaping Breast Cancer Screening
CCSN President & CEO Jackie Manthorne was one of several speakers at the Ontario Lung Association Breathing Policy Forum on Patient Engagement in Public Policy held in Toronto on Sept. 18, 2019. During this forum on patient group engagement within the drug submission process and patient group engagement within national Pharmacare, Manthorne presented information about CCSN and the dozens of patient group submissions that CCSN